Home › Ovarian Epithelial Carcinoma › Pennsylvania
Ovarian Epithelial Carcinoma clinical trials in Pennsylvania
10 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- St. Lukes University Hospital /ID# 274362, Bethlehem
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, York
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- St. Lukes University Health Network, Bethlehem
- Ann B Barshinger Cancer Institute, Lancaster
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007CT-95 in Advanced Cancers Associated With Mesothelin Expression
- University of Pennsylvania, Philadelphia
- Context Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06756035A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · Women · Updated Feb 3, 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Alliance Cancer Specialists, PC, Doylestown
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.